Stamford, Connecticut-based Purdue Pharma has announced leadership changes that include adding veteran Marc Kesselman as senior vice president and general counsel.

Privately held Purdue, maker of the popular opioid Oxycontin, has been under heavy criticism recently amid local, state and federal governments’ legal attacks on pharma companies for their role in promoting opioid abuse and addiction.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]